$175 says piper sandler 10XHOT on the daily very volatile analyst $100-175 let's see if we can get $21.50 first.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−13.35 USD
−87.68 M USD
15.53 M USD
2.54 M
About Aligos Therapeutics, Inc.
Sector
CEO
Lawrence M. Blatt
Headquarters
South San Francisco
Website
Founded
2018
FIGI
BBG00QX7QH68
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Trade Review - ALGS
When stock showed up in screener showed a bullish continuation pattern on daily timeframe and a potential failure test / pullback on the higher timeframe downtrend, a bit near mean but was added to watchlist.
Execution chart.
Trade Overview
• Structure: Bullish Continuation (D)
• Position: Nea
ALGS | Aligos Therapeutics, Inc. Healthcare US Stocks NASDAQ
📈 Technical Chart Patterns & Trend Analysis 📉
Identifying potential trading opportunities based on trend analysis:
bullish divergence can on double bottom can be seen on daily frame
buy stop order will be a suitable option for trading in this scenario .
$ALGS can rise in the next daysContextual immersion trading strategy idea.
Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
The demand for shares of the company looks higher than the supply.
This and other conditions can c
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALGS is 19.59 USD — it has decreased by −1.62% in the past 24 hours. Watch Aligos Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aligos Therapeutics, Inc. stocks are traded under the ticker ALGS.
ALGS stock has fallen by −3.19% compared to the previous week, the month change is a 146.67% rise, over the last year Aligos Therapeutics, Inc. has showed a 14.46% increase.
We've gathered analysts' opinions on Aligos Therapeutics, Inc. future price: according to them, ALGS price has a max estimate of 175.00 USD and a min estimate of 60.00 USD. Watch ALGS chart and read a more detailed Aligos Therapeutics, Inc. stock forecast: see what analysts think of Aligos Therapeutics, Inc. and suggest that you do with its stocks.
ALGS reached its all-time high on Jan 20, 2021 with the price of 937.75 USD, and its all-time low was 6.76 USD and was reached on Oct 8, 2024. View more price dynamics on ALGS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALGS stock is 14.08% volatile and has beta coefficient of −0.17. Track Aligos Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aligos Therapeutics, Inc. there?
Today Aligos Therapeutics, Inc. has the market capitalization of 65.30 M, it has decreased by −6.47% over the last week.
Yes, you can track Aligos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aligos Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ALGS earnings for the last quarter are −3.07 USD per share, whereas the estimation was −2.16 USD resulting in a −42.35% surprise. The estimated earnings for the next quarter are −2.50 USD per share. See more details about Aligos Therapeutics, Inc. earnings.
Aligos Therapeutics, Inc. revenue for the last quarter amounts to 1.27 M USD, despite the estimated figure of 333.33 K USD. In the next quarter, revenue is expected to reach 433.33 K USD.
ALGS net income for the last quarter is −19.26 M USD, while the quarter before that showed 5.06 M USD of net income which accounts for −480.54% change. Track more Aligos Therapeutics, Inc. financial stats to get the full picture.
No, ALGS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 66.00 employees. See our rating of the largest employees — is Aligos Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aligos Therapeutics, Inc. EBITDA is −91.86 M USD, and current EBITDA margin is −543.23%. See more stats in Aligos Therapeutics, Inc. financial statements.
Like other stocks, ALGS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aligos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aligos Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aligos Therapeutics, Inc. stock shows the neutral signal. See more of Aligos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.